Physician profile

Elizabeth A Sayers

Physician Assistant · Holland, MI

NPI 1922025725

$2,672.60

in general payments reported to CMS, 2019-2025

39 companies · $249 in 2025

The $249 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).

See the full distribution for Physician Assistant

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,906.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $514.15 2023-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $212.30 2023-2025 Zepbound, Jardiance, Mounjaro
Novartis Pharmaceuticals Corporation $187.94 2021-2023
Dexcom, INC. $172.94 2024-2025 Dexcom G6 Transmitter
Amgen INC. $146.25 2021-2024 Evenity, Prolia, Repatha
Boehringer Ingelheim Pharmaceuticals, INC. $122.34 2021-2024 Jardiance
Cardiovascular Systems INC. $113.91 2021-2023 Diamondback Peripheral
Philips North America LLC $94.66 2022-2023
Abbott Laboratories $89.00 2021-2025 Diamondback Peripheral, Freestyle Libre 3
Corcept Therapeutics $77.64 2024 Korlym
Xeris Pharmaceuticals, INC. $75.32 2024-2025 Gvoke Hypopen, Recorlev
Merck Sharp & Dohme LLC $69.89 2021-2023 Verquvo
Janssen Pharmaceuticals, INC $66.90 2021-2023 Xarelto
Madrigal Pharmaceuticals $66.45 2024-2025 Resmetirom, Rezdiffra
Boston Scientific Corporation $58.26 2022-2023 Watchman Access System
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Radius Health, INC. $54.74 2023-2024 Tymlos
Ascendis Pharma Endocrinology INC $44.14 2024-2025 Yorvipath
Kiniksa Pharmaceuticals, LTD. $43.96 2023 Arcalyst
Tandem Diabetes Care, INC. $40.68 2024-2025 T:Slim X2 Insulin Pump With Control-Iq
Neurocrine Biosciences, INC. $36.34 2024-2025
Antares Pharma, INC. $36.18 2024 Xyosted
Teleflex LLC $32.09 2022
Pfizer INC. $31.29 2023
Regeneron Healthcare Solutions, INC. $27.98 2022
Irhythm Technologies, INC. $25.52 2021
Sanofi-Aventis U.S. LLC $24.86 2024
Medtronic, INC. $23.31 2022
Lexicon Pharmaceuticals, INC. $18.26 2024
Astellas Pharma US INC $17.44 2021
Angiodynamics, INC. $17.35 2023 Venacure 1470 Pro
Kowa Pharmaceuticals America, INC. $17.30 2022
Bayer Healthcare Pharmaceuticals INC. $16.02 2024
Ibsa Pharma INC. $15.69 2024 Tirosint, Licart
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $15.36 2023 Lifevest
Currax Pharmaceuticals LLC $14.31 2024 Contrave
Chiesi USA, INC. $13.80 2024 Mycapssa
Alnylam Pharmaceuticals INC. $13.39 2022
Atricure, INC. $12.82 2021
Astrazeneca Pharmaceuticals LP $11.82 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Elizabeth A Sayers

$2,672.60

in general payments reported 2019-2025

Years
2021-2025
Top company
Novo Nordisk INC
Context
The $249 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/10530043/elizabeth-a-sayers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.